KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Total Non-Current Liabilities: 2009-2025

Historic Total Non-Current Liabilities for Charles River Laboratories International (CRL) over the last 17 years, with Sep 2025 value amounting to $3.9 billion.

  • Charles River Laboratories International's Total Non-Current Liabilities fell 1.67% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year decrease of 1.67%. This contributed to the annual value of $3.8 billion for FY2024, which is 11.31% down from last year.
  • As of Q3 2025, Charles River Laboratories International's Total Non-Current Liabilities stood at $3.9 billion, which was down 2.57% from $4.0 billion recorded in Q2 2025.
  • In the past 5 years, Charles River Laboratories International's Total Non-Current Liabilities registered a high of $4.6 billion during Q2 2022, and its lowest value of $3.4 billion during Q1 2021.
  • For the 3-year period, Charles River Laboratories International's Total Non-Current Liabilities averaged around $4.1 billion, with its median value being $4.1 billion (2023).
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first spiked by 41.09% in 2021, then declined by 11.31% in 2024.
  • Charles River Laboratories International's Total Non-Current Liabilities (Quarterly) stood at $4.2 billion in 2021, then climbed by 5.13% to $4.4 billion in 2022, then decreased by 2.08% to $4.3 billion in 2023, then dropped by 11.31% to $3.8 billion in 2024, then declined by 1.67% to $3.9 billion in 2025.
  • Its Total Non-Current Liabilities stands at $3.9 billion for Q3 2025, versus $4.0 billion for Q2 2025 and $4.1 billion for Q1 2025.